MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Bicycle Therapeutics plc (NASDAQ: BCYC)*
Organization & Developments: Bicycle Therapeutics
Parents
Bicycle Therapeutics plc (NASDAQ: BCYC)*
Children
*Proprietary phage display screening platform which directs the evolution of bicyclic peptides to rapidly and empirically generate optimized novel drug candidates
*The company is using a new platform it calls bicycles, which involves short molecular scaffolds that form two loops. These loops bind to specific targets.
*The science behind bicycle peptides originated in the labs of the company’s co-founder Greg Winter, 2018 Nobel Prize winner British biochemist who is known for his work on monoclonal antibodies.
2019: Bicycle Therapeutics: Novel Bicycle Peptide Technology Could Disrupt The Monoclonal Antibodies Market_seekingalpha.com
2020: Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors
2020: Bicycle Therapeutics: Early Stage Platform Technology Play With Multiple Upside Drivers_seekingalpha.com
2021: Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next
2022: Bicycle Therapeutics (BCYC) Investor Presentation - Slideshow_ seekingalpha.com
2022: Bicycle Therapeutics: An Oncology Play With Big Potential
2023: Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet_
2023: Bicycle Therapeutics: Pedaling Through Uncertainty
2023: Novartis to ride with Bicycle in radiopharmaceuticals deal that could cruise to $1.7B
2024: Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
2024: Bicycle Therapeutics Is Looking Increasingly Attractive
2024: Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern_ seekingalpha.com
2024: Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
2024: Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform
2024: Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
2025: Bicycle lays off 25% of workforce as Genentech rides away from R&D pact
2025: Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data
Jumps
Finance & Acquisitions: Bicycle Therapeutics
Key People: Bicycle Therapeutics